Login / Signup

Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting.

Neal BhatiaJayme HeimJ Gabriel VasquezTina BhutaniBrad SchenkelRanga GogineniJohn Koo
Published in: The Journal of dermatological treatment (2024)
Tildrakizumab improved long-term HRQoL in patients with psoriasis in a real-world setting.
Keyphrases
  • coronary artery disease
  • open label
  • early onset
  • atopic dermatitis
  • randomized controlled trial
  • study protocol
  • placebo controlled